Peptides

Mechanism: Combines copper-peptide signaling with two research compounds discussed around tissue-repair pathways; a combined mechanism has not been established clinically.

Evidence: The named blend has no established clinical evidence as a formulation. Evidence must be assessed component by component, and the injectable claims are generally weaker than topical GHK-Cu research.

• Local Pep-Pedia-derived dataset — Identity and named-blend context only; old dose, cycle, storage, and outcome strings were excluded.
• Andrew Huberman — Notes that BPC-157 lacks randomized human trials.
• Andrew Huberman — Independent identity and purity testing context for peptide products.

Mechanism: Pairs copper-peptide signaling with three research peptides discussed around tissue and inflammatory pathways; the combination itself has not been clinically characterized.

Evidence: Evidence is extrapolated from four separate components. The named combination has no established human evidence, and several components remain primarily preclinical research topics.

• Local Pep-Pedia-derived dataset — Identity and blend composition provenance only.
• Andrew Huberman — Broad peptide-category framing rather than evidence for this proprietary blend.
• Andrew Huberman — Independent product-testing context.

Mechanism: Combines two compounds discussed around angiogenesis, cell migration, and tissue-repair signaling; a clinically validated combined mechanism is not established.

Evidence: The blend has no established clinical evidence. BPC-157 lacks randomized human trials, while TB-500 product identity should not be conflated with full-length thymosin beta-4 research.

• Local Pep-Pedia-derived dataset — Named blend and composition provenance only.
• Andrew Huberman — Explicitly distinguishes BPC-157 discussion from randomized human-trial evidence.

Mechanism: Groups research compounds associated with tissue and inflammatory pathways; no validated mechanism exists for the fixed blend.

Evidence: The formulation does not have established clinical evidence. Its name is promotional, and the evidence base is limited to separate component research.

• Local Pep-Pedia-derived dataset — Blend identity and calculator composition provenance only.
• Andrew Huberman — Independent product-testing context is especially relevant to compounded blends.

Mechanism: CJC-1295 without DAC is a short-acting GHRH analog; ipamorelin is a ghrelin-receptor agonist. Both can signal toward pulsatile growth-hormone release.

Evidence: The physiological rationale comes from the two signaling pathways, but the fixed commercial blend has limited direct human evidence and should not inherit claims made for other GH-axis drugs.

• Local Pep-Pedia-derived dataset — Paired-protocol identity and calculator composition provenance only.
• Andrew Huberman — Places GH secretagogues within a broader peptide-category framework.

Mechanism: No blend-level mechanism can be assigned until the actual components are known.

Evidence: There is no single Beauty formulation to evaluate. Any evidence review must start with the exact ingredients and amounts on the specific product label.

• Local Pep-Pedia-derived dataset — Used only to preserve the common vendor name; no standard formula was inferred.
• Andrew Huberman — Independent identity and purity testing is relevant when a marketing name does not define a standard formula.

Mechanism: Preclinical work explores angiogenesis, nitric-oxide signaling, cell migration, and tissue-repair pathways; a therapeutic human mechanism is not established.

Evidence: Mechanistic and animal findings do not establish human benefit. Andrew Huberman explicitly notes the lack of randomized human trials.

• Local Pep-Pedia-derived dataset — Identity and community context only; dosing and outcome claims were excluded.
• Andrew Huberman — States that BPC-157 lacks randomized human trials.
• Andrew Huberman — Independent product-testing context.

Mechanism: Thymosin beta-4 biology includes actin binding, cell migration, and wound-repair signaling; the identity and equivalence of TB-500 products require care.

Evidence: Some human research exists for full-length or formulated thymosin beta-4, but that evidence cannot automatically be assigned to products sold as TB-500.

• Local Pep-Pedia-derived dataset — Identity and community context only; kept distinct from full-length thymosin beta-4.
• Andrew Huberman — Independent identity and purity testing context.

Mechanism: Binds copper and is studied in extracellular-matrix, wound-remodeling, and gene-signaling contexts.

Evidence: Human cosmetic research is largely topical. It should not be used as direct support for injectable dosing, systemic outcomes, or proprietary blends.

• Local Pep-Pedia-derived dataset — Topical protocols and injectable calculator identity were kept separate during curation.
• Andrew Huberman — Independent testing context for nonstandard injectable products.

Mechanism: Mimics growth-hormone-releasing hormone signaling at the pituitary, with a shorter exposure profile than the DAC-bound analog.

Evidence: Human evidence for this short-acting formulation and common compounded protocols is limited. Findings from CJC-1295 with DAC should not be silently transferred to it.

• Local Pep-Pedia-derived dataset — Identity and “without DAC” distinction only.
• Andrew Huberman — Growth-hormone secretagogue category context.

Mechanism: The DAC design binds circulating albumin and extends GHRH-receptor stimulation compared with short-acting analogs.

Evidence: Early human trials characterize hormone responses and pharmacokinetics. They do not establish broad anti-aging, body-composition, or performance outcomes.

• Local Pep-Pedia-derived dataset — Identity and long-acting DAC distinction only.
• Andrew Huberman — Growth-hormone secretagogue category context.

Mechanism: Activates the ghrelin receptor to stimulate growth-hormone release, with selectivity that differentiates it from some earlier secretagogues.

Evidence: Pharmacology and small studies do not establish the recovery, sleep, body-composition, or longevity claims commonly attached to compounded use.

• Local Pep-Pedia-derived dataset — Identity and paired-protocol context only.
• Andrew Huberman — Growth-hormone secretagogue category context.

Mechanism: Stimulates pituitary GHRH receptors and endogenous growth-hormone release.

Evidence: Historical human use supports its GHRH activity, not broad claims about sleep, recovery, body composition, or aging. Andrew Huberman’s PSA/sleep post is a personal anecdote, not a trial.

• Local Pep-Pedia-derived dataset — Identity and community context only.
• Andrew Huberman — Personal PSA and sleep anecdote; explicitly not clinical outcome evidence.

Mechanism: Stimulates endogenous growth-hormone release through GHRH receptors, influencing IGF-1 and visceral-fat metabolism.

Evidence: Condition-specific approval and trials make this evidence base more mature than most entries here. That does not generalize to routine body recomposition or anti-aging use.

• Local Pep-Pedia-derived dataset — Identity and community context only; condition-specific evidence remains the important distinction.
• Andrew Huberman — Places tesamorelin within the GH-axis peptide category.

Mechanism: Designed around a region of growth hormone associated with lipolytic signaling while attempting to avoid full GH growth effects.

Evidence: Human development included obesity studies, yet efficacy was not established as hoped. Community positioning should not erase that negative or inconclusive history.

• Local Pep-Pedia-derived dataset — Identity and historical community context only.
• Andrew Huberman — Broad metabolic peptide-category context.

Mechanism: Activates GLP-1 receptors, affecting appetite, gastric emptying, insulin signaling, and glucagon regulation.

Evidence: This has far more mature evidence than most entries here. Layne Norton emphasizes reduced energy intake as a major mechanism and questions universal use; that framing does not replace individualized medical assessment.

• Local Pep-Pedia-derived dataset — Identity and catalog provenance only.
• Layne Norton — Frames reduced energy intake as central to GLP-1-associated weight loss.
• Layne Norton — Raises the question of whether use should be universal rather than assuming it is.

Mechanism: Activates GIP and GLP-1 receptors, influencing appetite, glucose regulation, insulin signaling, and gastric function.

Evidence: Evidence supports substantial metabolic effects in studied populations. Layne Norton’s energy-intake framing and non-universal-use question keep the mechanism and decision context grounded.

• Local Pep-Pedia-derived dataset — Identity and catalog provenance only.
• Layne Norton — Energy-intake framing for incretin-associated weight loss.
• Layne Norton — Questions the idea of universal GLP-1 use.

Mechanism: Combines GIP and GLP-1 receptor agonism with glucagon-receptor activity to affect appetite, glucose regulation, and energy expenditure.

Evidence: Human trials support meaningful metabolic effects, while longer-term outcomes and broader claims remain under study. Attia’s geroprotection/cognition comments and Patrick’s genetics context are emerging hypotheses, not settled indications.

• Local Pep-Pedia-derived dataset — Identity and catalog provenance only.
• Peter Attia — Emerging GLP-1 geroprotection and cognition context; speculative beyond established metabolic outcomes.
• Rhonda Patrick — Emerging GLP-1 receptor genetics context; not direct retatrutide outcome evidence.

Mechanism: Studied as a mitochondrial stress signal that can influence cellular metabolism, AMPK-related pathways, and adaptation to energetic demand.

Evidence: Human observational and early translational work does not establish the benefits claimed for exogenous MOTS-c products.

• Local Pep-Pedia-derived dataset — Identity and community context only.
• Andrew Huberman — Broad metabolic and mitochondrial peptide-category context.

Mechanism: Studied for effects on inflammatory transcription and immune signaling, including pathways often described around NF-kappa-B.

Evidence: The research base is predominantly preclinical. Community use and blend inclusion do not establish clinical efficacy.

• Local Pep-Pedia-derived dataset — Identity and community context only.
• Andrew Huberman — Broad immune and tissue peptide-category context, not direct evidence for KPV.

Mechanism: Modulates innate and adaptive immune signaling, including dendritic-cell and T-cell activity.

Evidence: Human trials and international medical use exist, but results depend on the condition and regimen. That does not support general “immune boosting” claims.

• Local Pep-Pedia-derived dataset — Identity and community context only; condition-specific evidence should remain attached.
• Andrew Huberman — Broad immune-peptide category context.

Mechanism: Activates melanocortin-1 receptors and promotes eumelanin production.

Evidence: Afamelanotide has condition-specific human evidence as a controlled implant. That formulation and oversight do not validate unregulated products sold as Melanotan I.

• Local Pep-Pedia-derived dataset — Identity and community context only; kept distinct from the afamelanotide implant.
• Andrew Huberman — Independent identity and purity testing context.

Mechanism: Activates multiple melanocortin receptors, affecting pigmentation and central pathways involved in appetite and sexual response.

Evidence: Small human studies and derivative-drug development do not establish the safety or quality of Melanotan II sold through research-product channels.

• Local Pep-Pedia-derived dataset — Identity and community context only.
• Andrew Huberman — Independent product-testing context.

Mechanism: Acts centrally through melanocortin receptors involved in sexual-response pathways rather than through peripheral vasodilation alone.

Evidence: A regulated bremelanotide product has human trial and clinical-use evidence for a defined indication. That evidence should not be transferred wholesale to compounded or research-market PT-141.

• Local Pep-Pedia-derived dataset — Identity and community context only; kept distinct from branded bremelanotide.
• Andrew Huberman — Independent identity and purity testing context for nonstandard products.

Mechanism: Proposed to influence sleep and neuroendocrine regulation, but a consistent therapeutic mechanism has not been established.

Evidence: Small and older studies are heterogeneous, and the peptide’s endogenous role remains debated. It is not an established insomnia treatment.

• Local Pep-Pedia-derived dataset — Identity and historical community context only.
• Andrew Huberman — Broad peptide-category context, not direct support for DSIP efficacy.

Mechanism: Proposed effects include pineal signaling, oxidative-stress pathways, and telomerase-related activity, with uncertain clinical relevance.

Evidence: Much of the cited work is small, older, or not easily generalized. Telomerase and lifespan narratives should be treated as hypotheses rather than demonstrated human outcomes.

• Local Pep-Pedia-derived dataset — Identity and longevity-community context only.
• Andrew Huberman — Broad longevity peptide-category context, not verification of Epitalon claims.